Cover Image
市場調查報告書

藥物分析:Synribo (omacetaxine)

Drugs Analysis: Synribo

出版商 Datamonitor Healthcare 商品編碼 603920
出版日期 內容資訊 英文 12 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物分析:Synribo (omacetaxine) Drugs Analysis: Synribo
出版日期: 2017年12月07日 內容資訊: 英文 12 Pages
簡介

提供著本報告提供慢性骨髓性白血病 (CML) 治療藥的Synribo (omacetaxine) 的相關調查,SWOT分析,藥物簡介,及臨床實驗資料等。

產品簡介

  • Synribo : 慢性骨髓性白血病 (CML)

圖表

  • CML用Synribo :SWOT分析
  • Datamonitor Healthcare的藥物評估摘要:CML用Synribo

圖表

  • Synribo:藥物簡介
  • CML中Synribo的重要臨床實驗資料
目錄
Product Code: DMKC0090996

Drug Overview

Synribo (omacetaxine mepesuccinate; Teva/Hospira) is a subcutaneously formulated, semisynthetic form of homoharringtonine, a naturally occurring alkaloid. In vitro studies show that Synribo binds to the ribosomal A-site cleft, inhibiting synthesis of a number of key oncoproteins. These oncoproteins include mcl-1 (an apoptosis inhibitor), cyclin-D1 (a promoter of cell proliferation), and c-Myc (a cell differentiation inhibitor).

Synribo has suffered due to its late entrance into the chronic myeloid leukemia (CML) market and an unfavorable subcutaneous administration route compared to other marketed drugs. The drug has displayed activity against T315I mutation-positive disease, but Iclusig (ponatinib; Takeda/Incyte/Otsuka) displays similar activity and is available in an orally administered formulation. Therefore, Synribo will continue to see only minimal uptake in CML.

TABLE OF CONTENTS

PRODUCT PROFILES

  • Synribo : Chronic myeloid leukemia (CML)

LIST OF FIGURES

  • Figure 1: Synribo for CML - SWOT analysis
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Synribo for CML
  • Figure 3: Datamonitor Healthcare's drug assessment summary of Synribo for CML

LIST OF TABLES

  • Table 1: Synribo drug profile
  • Table 2: Synribo pivotal trial data in CML
Back to Top